用异体恒定自然杀伤 T 细胞(iNKT)克服程序性细胞死亡蛋白 1(PD-1)阻断的耐药性
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).
肿瘤细胞治疗研究
ALL SOURCES
把在研试验和前沿论文合在一起看,按时间倒序排列。本页条数 = 前沿论文 + 临床试验两块之和(导航里的「临床试验」板块只收在招的那部分,不另计入)。
Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).
Unravelling diagnostic clusters and immune landscapes of disulfidptosis patterns in gastric cancer through bioinformatic assay.
IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment.
First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer.
BVAC-B 单药治疗具有安全的毒性特征,但临床活性有限;然而,它在经过大量预治疗的 HER2 阳性胃癌患者中激活了免疫细胞。有必要在更早期治疗中采用 BVAC-B 及联合治疗以评估临床疗效。
CD4(-)/CD8(-) double-negative tumor-infiltrating lymphocytes expanded from solid tumor tissue suppress the proliferation of tumor cells in an MHC-inde
胃癌来源的 DN-TIL 能够在体外和体内靶向肿瘤细胞。DN-TIL 有潜力作为实体癌的过继细胞疗法,兼具 DNT 和 TIL 的优势。
A combined analysis of bulk and single-cell sequencing data reveals that depleted extracellular matrix and enhanced immune processes co-contribute to
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。